Difference between revisions of "Team:DTU-Denmark/Description"
m (navbar upgrade) |
m |
||
| Line 2: | Line 2: | ||
<head> | <head> | ||
| + | |||
| + | <script> | ||
| + | |||
| + | $(document).ready(function(){ | ||
| + | |||
| + | var scroll_start = 0; | ||
| + | var startchange = $('#startchange'); | ||
| + | var offset = startchange.offset(); | ||
| + | $(document).scroll(function() { | ||
| + | |||
| + | scroll_start = $(this).scrollTop(); | ||
| + | if (scroll_start > offset.top - 400) { | ||
| + | $('.navbar').addClass('scrolledpastnav'); | ||
| + | $('progress').addClass('scrolledpastnav'); | ||
| + | $('.dropdown-content').addClass('scrolledpastnav'); | ||
| + | } | ||
| + | else { | ||
| + | $('.navbar').removeClass('scrolledpastnav'); | ||
| + | $('progress').removeClass('scrolledpastnav'); | ||
| + | $('.dropdown-content').removeClass('scrolledpastnav'); | ||
| + | } | ||
| + | }); | ||
| + | }); | ||
| + | |||
| + | </script> | ||
<!-- importing style sheet --> | <!-- importing style sheet --> | ||
| Line 248: | Line 273: | ||
/****************************************************************************************************************/ | /****************************************************************************************************************/ | ||
| − | + | /***** defines key properties of the nav bar *****/ | |
| − | + | ||
#windowcontent nav { | #windowcontent nav { | ||
margin: 0px; | margin: 0px; | ||
padding: 0px; | padding: 0px; | ||
| + | overflow: hidden; | ||
top: 0px; | top: 0px; | ||
width: 100%; | width: 100%; | ||
| Line 269: | Line 294: | ||
#windowcontent .navbar { | #windowcontent .navbar { | ||
| + | -webkit-transition: background 1s; | ||
| + | transition: background 1s; | ||
| + | background-image: -webkit-linear-gradient(180deg, rgba(40,40,40,0.6), rgba(150,150,150,0.3)); | ||
| + | background-image: -o-linear-gradient(180deg, rgba(40,40,40,0.6), rgba(150,150,150,0.3)); | ||
| + | background-image: -moz-linear-gradient(180deg, rgba(40,40,40,0.6), rgba(150,150,150,0.3)); | ||
| + | background-image: linear-gradient(180deg, rgba(40,40,40,0.6), rgba(150,150,150,0.3)); | ||
| + | box-shadow: 0px 0px 12px 0px rgba(0,0,0,0.3); | ||
| + | } | ||
| + | |||
| + | /***** sets the color of the nav bar when scrolled down to the main text TRANSITIONS CANNOT BE USED HERE *****/ | ||
| + | |||
| + | #windowcontent .navbar.scrolledpastnav { | ||
| + | -webkit-transition: background 1.5s; | ||
| + | transition: background 1.5s; | ||
background-color: rgba(20,20,20,1); | background-color: rgba(20,20,20,1); | ||
box-shadow: 0px 0px 12px 0px rgba(0,0,0,0.7); | box-shadow: 0px 0px 12px 0px rgba(0,0,0,0.7); | ||
| Line 280: | Line 319: | ||
background: -moz-linear-gradient(180deg, rgba(0,0,0,0.2), rgba(0,0,0,0.1)); | background: -moz-linear-gradient(180deg, rgba(0,0,0,0.2), rgba(0,0,0,0.1)); | ||
background: linear-gradient(180deg, rgba(0,0,0,0.2), rgba(0,0,0,0.1)); | background: linear-gradient(180deg, rgba(0,0,0,0.2), rgba(0,0,0,0.1)); | ||
| + | } | ||
| + | |||
| + | /***** sets layout of dropdown menu when nav bar changes layout *****/ | ||
| + | |||
| + | #windowcontent .dropdown-content.scrolledpastnav { | ||
| + | -webkit-transition: background 1.5s; | ||
| + | transition: background 1.5s; | ||
} | } | ||
| Line 306: | Line 352: | ||
#windowcontent .dropdown-content { | #windowcontent .dropdown-content { | ||
| + | -webkit-transition: background 1.5s; /* Safari */ | ||
| + | transition: background 1.5s; | ||
display: none; | display: none; | ||
position: absolute; | position: absolute; | ||
| Line 336: | Line 384: | ||
background-color: rgb(235,235,235); | background-color: rgb(235,235,235); | ||
} | } | ||
| − | |||
| − | |||
/****************************************************************************************************************/ | /****************************************************************************************************************/ | ||
| Line 485: | Line 531: | ||
<div class="colp-12 rmvpadmarg" id="startchange"> | <div class="colp-12 rmvpadmarg" id="startchange"> | ||
| − | <h1 class="bottomborder">Project description</h1> | + | <h1 id="startchange" class="bottomborder">Project description</h1> |
<p>Envenomation by snakebite is one of the most neglected diseases with an estimated 5 million bites. These result in about 100,000 deaths and 400,000 disabilities annually [1]. The only effective treatment is animal derived antivenoms, which frequently causes adverse reactions [2]. As a result they are often only administered as a last resort.</p> | <p>Envenomation by snakebite is one of the most neglected diseases with an estimated 5 million bites. These result in about 100,000 deaths and 400,000 disabilities annually [1]. The only effective treatment is animal derived antivenoms, which frequently causes adverse reactions [2]. As a result they are often only administered as a last resort.</p> | ||
| Line 502: | Line 548: | ||
| − | + | <p>Envenomation by snakebite is one of the most neglected diseases with an estimated 5 million bites. These result in about 100,000 deaths and 400,000 disabilities annually [1]. The only effective treatment is animal derived antivenoms, which frequently causes adverse reactions [2]. As a result they are often only administered as a last resort.</p> | |
| + | <p>One of the major problems related to treatment of snake bites concerns the lack of identification of the snake. When bitten, it is difficult for most people to remember details about the snake, which makes it almost impossible to confidently administer the correct specific antivenom. Currently, if the snake cannot be identified, multispecies antivenom is used in a consequently higher dose leading to more severe side effects. By solving the venom identification problem it could potentially increase the survival rate of snake bite victims. This is due to decreased diagnosis time and less amount of antivenom necessary for treatment, thereby causing fewer adverse reactions in the patient [3].</p> | ||
| + | <p>We aim to create a novel diagnostic platform by using synthetic biology derived protease activity assay to identify specific venom enzymes that, by developing suitable substrates, can investigate the relative composition of specific venom components in a blood sample. Our goal is to create a diagnostic tool that would make it possible for a clinician to quickly determine which antivenom is necessary, or if it is necessary at all.</p> | ||
| + | <p>Envenomation by snakebite is one of the most neglected diseases with an estimated 5 million bites. These result in about 100,000 deaths and 400,000 disabilities annually [1]. The only effective treatment is animal derived antivenoms, which frequently causes adverse reactions [2]. As a result they are often only administered as a last resort.</p> | ||
| + | <p>One of the major problems related to treatment of snake bites concerns the lack of identification of the snake. When bitten, it is difficult for most people to remember details about the snake, which makes it almost impossible to confidently administer the correct specific antivenom. Currently, if the snake cannot be identified, multispecies antivenom is used in a consequently higher dose leading to more severe side effects. By solving the venom identification problem it could potentially increase the survival rate of snake bite victims. This is due to decreased diagnosis time and less amount of antivenom necessary for treatment, thereby causing fewer adverse reactions in the patient [3].</p> | ||
| + | <p>We aim to create a novel diagnostic platform by using synthetic biology derived protease activity assay to identify specific venom enzymes that, by developing suitable substrates, can investigate the relative composition of specific venom components in a blood sample. Our goal is to create a diagnostic tool that would make it possible for a clinician to quickly determine which antivenom is necessary, or if it is necessary at all.</p> | ||
| + | <p>Envenomation by snakebite is one of the most neglected diseases with an estimated 5 million bites. These result in about 100,000 deaths and 400,000 disabilities annually [1]. The only effective treatment is animal derived antivenoms, which frequently causes adverse reactions [2]. As a result they are often only administered as a last resort.</p> | ||
| + | <p>One of the major problems related to treatment of snake bites concerns the lack of identification of the snake. When bitten, it is difficult for most people to remember details about the snake, which makes it almost impossible to confidently administer the correct specific antivenom. Currently, if the snake cannot be identified, multispecies antivenom is used in a consequently higher dose leading to more severe side effects. By solving the venom identification problem it could potentially increase the survival rate of snake bite victims. This is due to decreased diagnosis time and less amount of antivenom necessary for treatment, thereby causing fewer adverse reactions in the patient [3].</p> | ||
| + | <p>We aim to create a novel diagnostic platform by using synthetic biology derived protease activity assay to identify specific venom enzymes that, by developing suitable substrates, can investigate the relative composition of specific venom components in a blood sample. Our goal is to create a diagnostic tool that would make it possible for a clinician to quickly determine which antivenom is necessary, or if it is necessary at all.</p> | ||
</div> | </div> | ||
| Line 573: | Line 627: | ||
<!-- This div ending is windowcontent. Everything should be before this --> | <!-- This div ending is windowcontent. Everything should be before this --> | ||
</div> | </div> | ||
| + | |||
| + | |||
| + | |||
</body> | </body> | ||
</html> | </html> | ||
Revision as of 17:57, 17 July 2017
Project description
Envenomation by snakebite is one of the most neglected diseases with an estimated 5 million bites. These result in about 100,000 deaths and 400,000 disabilities annually [1]. The only effective treatment is animal derived antivenoms, which frequently causes adverse reactions [2]. As a result they are often only administered as a last resort.
One of the major problems related to treatment of snake bites concerns the lack of identification of the snake. When bitten, it is difficult for most people to remember details about the snake, which makes it almost impossible to confidently administer the correct specific antivenom. Currently, if the snake cannot be identified, multispecies antivenom is used in a consequently higher dose leading to more severe side effects. By solving the venom identification problem it could potentially increase the survival rate of snake bite victims. This is due to decreased diagnosis time and less amount of antivenom necessary for treatment, thereby causing fewer adverse reactions in the patient [3].
We aim to create a novel diagnostic platform by using synthetic biology derived protease activity assay to identify specific venom enzymes that, by developing suitable substrates, can investigate the relative composition of specific venom components in a blood sample. Our goal is to create a diagnostic tool that would make it possible for a clinician to quickly determine which antivenom is necessary, or if it is necessary at all.
References:
[1] Chippaux JP (1998). Snake-bites: appraisal of the global situation. Bulletin of the World Health Organization, 76(5),515-24.
[2] Gutiérrez JM, León G, Lomonte B, Angulo Y (2011). Antivenoms for Snakebite Envenomings. Inflammation and Allergy. Drug Targets 10(5), 369–80.
[3] Warrell D, Gutierrez JM, Padilla A (2007). Rabies and Envenomings: a Neglected Public Health Issue: Report of a Consultative Meeting. World Health Organization, Geneva.
Envenomation by snakebite is one of the most neglected diseases with an estimated 5 million bites. These result in about 100,000 deaths and 400,000 disabilities annually [1]. The only effective treatment is animal derived antivenoms, which frequently causes adverse reactions [2]. As a result they are often only administered as a last resort.
One of the major problems related to treatment of snake bites concerns the lack of identification of the snake. When bitten, it is difficult for most people to remember details about the snake, which makes it almost impossible to confidently administer the correct specific antivenom. Currently, if the snake cannot be identified, multispecies antivenom is used in a consequently higher dose leading to more severe side effects. By solving the venom identification problem it could potentially increase the survival rate of snake bite victims. This is due to decreased diagnosis time and less amount of antivenom necessary for treatment, thereby causing fewer adverse reactions in the patient [3].
We aim to create a novel diagnostic platform by using synthetic biology derived protease activity assay to identify specific venom enzymes that, by developing suitable substrates, can investigate the relative composition of specific venom components in a blood sample. Our goal is to create a diagnostic tool that would make it possible for a clinician to quickly determine which antivenom is necessary, or if it is necessary at all.
Envenomation by snakebite is one of the most neglected diseases with an estimated 5 million bites. These result in about 100,000 deaths and 400,000 disabilities annually [1]. The only effective treatment is animal derived antivenoms, which frequently causes adverse reactions [2]. As a result they are often only administered as a last resort.
One of the major problems related to treatment of snake bites concerns the lack of identification of the snake. When bitten, it is difficult for most people to remember details about the snake, which makes it almost impossible to confidently administer the correct specific antivenom. Currently, if the snake cannot be identified, multispecies antivenom is used in a consequently higher dose leading to more severe side effects. By solving the venom identification problem it could potentially increase the survival rate of snake bite victims. This is due to decreased diagnosis time and less amount of antivenom necessary for treatment, thereby causing fewer adverse reactions in the patient [3].
We aim to create a novel diagnostic platform by using synthetic biology derived protease activity assay to identify specific venom enzymes that, by developing suitable substrates, can investigate the relative composition of specific venom components in a blood sample. Our goal is to create a diagnostic tool that would make it possible for a clinician to quickly determine which antivenom is necessary, or if it is necessary at all.
Envenomation by snakebite is one of the most neglected diseases with an estimated 5 million bites. These result in about 100,000 deaths and 400,000 disabilities annually [1]. The only effective treatment is animal derived antivenoms, which frequently causes adverse reactions [2]. As a result they are often only administered as a last resort.
One of the major problems related to treatment of snake bites concerns the lack of identification of the snake. When bitten, it is difficult for most people to remember details about the snake, which makes it almost impossible to confidently administer the correct specific antivenom. Currently, if the snake cannot be identified, multispecies antivenom is used in a consequently higher dose leading to more severe side effects. By solving the venom identification problem it could potentially increase the survival rate of snake bite victims. This is due to decreased diagnosis time and less amount of antivenom necessary for treatment, thereby causing fewer adverse reactions in the patient [3].
We aim to create a novel diagnostic platform by using synthetic biology derived protease activity assay to identify specific venom enzymes that, by developing suitable substrates, can investigate the relative composition of specific venom components in a blood sample. Our goal is to create a diagnostic tool that would make it possible for a clinician to quickly determine which antivenom is necessary, or if it is necessary at all.
